AUG 19 2026
Xspray Pharma AB — Dasynoc (dasatinib)
for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)
About
Chronic myelogenous leukemia is a cancer affecting the body's blood-forming tissues. Dasynoc (dasatinib) is a tablet that blocks specific proteins which drive the uncontrolled growth of cancer cells. By inhibiting these proteins, the drug may help control the progression of the disease.
Pivotal trial
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. The efficacy of the drug in this kind of patients will also further be documented.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Dasynoc
- Xspray Pharma Highlights CML Data Differentiating Dasynoc and Nilopki - TipRanks
- Xspray's Dasynoc approval bid foiled again by FDA's manufacturer concerns - Fierce Pharma
- Xspray Pharma (Q2 review): Just ahead of Dasynoc PDUFA - tradingview.com
- Xspray Pharma provides regulatory update on its US product candidates Nilopki® and Dasynoc® and notes continued progress with its third-party manufacturer NerPharMa - tradingview.com
- FDA Rejects Dasatinib (Dasynoc) for Leukemia - Oncology News Central